These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 29649263)
1. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. Soukupova J; Zemankova P; Lhotova K; Janatova M; Borecka M; Stolarova L; Lhota F; Foretova L; Machackova E; Stranecky V; Tavandzis S; Kleiblova P; Vocka M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z PLoS One; 2018; 13(4):e0195761. PubMed ID: 29649263 [TBL] [Abstract][Full Text] [Related]
2. [CZECANCA: CZEch CAncer paNel for Clinical Application-- Design and Optimization of the Targeted Sequencing Panel for the Identification of Cancer Susceptibility in High-risk Individuals from the Czech Republic]. Soukupová J; Zemánková P; Kleiblová P; Janatová M; Kleibl Z Klin Onkol; 2016; 29 Suppl 1():S46-54. PubMed ID: 26691942 [TBL] [Abstract][Full Text] [Related]
3. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519 [TBL] [Abstract][Full Text] [Related]
4. Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis. Schenkel LC; Kerkhof J; Stuart A; Reilly J; Eng B; Woodside C; Levstik A; Howlett CJ; Rupar AC; Knoll JHM; Ainsworth P; Waye JS; Sadikovic B J Mol Diagn; 2016 Sep; 18(5):657-667. PubMed ID: 27376475 [TBL] [Abstract][Full Text] [Related]
5. Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Kamps R; Brandão RD; Bosch BJ; Paulussen AD; Xanthoulea S; Blok MJ; Romano A Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146134 [TBL] [Abstract][Full Text] [Related]
6. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691 [TBL] [Abstract][Full Text] [Related]
7. Classification of germline variants identified in cancer predisposition genetic testing - consensus of the CZECANCA consortium. Janatová M; Chvojka Š; Macháčková E; Soukupová J; Zemánková P; Nehasil P; Zavoral T; Hrušková L; Janíková KMK; Lhota F; Tavandzis S; Kleiblová P; Kleibl Z; Konzorcium C Klin Onkol; 2023; 37(6):431-439. PubMed ID: 38158231 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081 [TBL] [Abstract][Full Text] [Related]
9. Parallel DNA/RNA NGS Using an Identical Target Enrichment Panel in the Analysis of Hereditary Cancer Predisposition. Kleiblová P; Černá M; Zemánková P; Matějková K; Nehasil P; Hojný J; Horáčková K; Janatová M; Soukupová J; Šťastná B; Kleibl Z Folia Biol (Praha); 2024; 70(1):62-73. PubMed ID: 38830124 [TBL] [Abstract][Full Text] [Related]
10. Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes. Paulo P; Pinto P; Peixoto A; Santos C; Pinto C; Rocha P; Veiga I; Soares G; Machado C; Ramos F; Teixeira MR J Mol Diagn; 2017 Jul; 19(4):502-513. PubMed ID: 28529006 [TBL] [Abstract][Full Text] [Related]
11. Validation of the Oncomine Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation. Vidal AF; Ferraz RS; El-Husny A; Silva CS; Vinasco-Sandoval T; Magalhães L; Raiol-Moraes M; Barra WF; Pereira CLBL; de Assumpção PP; de Brito LM; Vialle RA; Santos S; Ribeiro-Dos-Santos Â; Ribeiro-Dos-Santos AM BMC Cancer; 2021 Apr; 21(1):363. PubMed ID: 33827469 [TBL] [Abstract][Full Text] [Related]
13. A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. Castellanos E; Gel B; Rosas I; Tornero E; Santín S; Pluvinet R; Velasco J; Sumoy L; Del Valle J; Perucho M; Blanco I; Navarro M; Brunet J; Pineda M; Feliubadaló L; Capellá G; Lázaro C; Serra E Sci Rep; 2017 Jan; 7():39348. PubMed ID: 28051113 [TBL] [Abstract][Full Text] [Related]
14. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754 [TBL] [Abstract][Full Text] [Related]
15. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. DiNardo CD; Routbort MJ; Bannon SA; Benton CB; Takahashi K; Kornblau SM; Luthra R; Kanagal-Shamanna R; Medeiros LJ; Garcia-Manero G; M Kantarjian H; Futreal PA; Meric-Bernstam F; Patel KP Cancer; 2018 Jul; 124(13):2704-2713. PubMed ID: 29682723 [TBL] [Abstract][Full Text] [Related]
16. Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Gupta S; Greenberg S; Grimmett J; Gaston D; Agarwal N; Lowrance W; Schiffman J; Kohlmann W Fam Cancer; 2017 Oct; 16(4):545-550. PubMed ID: 28315974 [TBL] [Abstract][Full Text] [Related]
17. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition. Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922 [TBL] [Abstract][Full Text] [Related]
18. Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines. Marcus RK; Geurts JL; Grzybowski JA; Turaga KK; Clark Gamblin T; Strong KA; Johnston FM Fam Cancer; 2015 Dec; 14(4):641-9. PubMed ID: 26108897 [TBL] [Abstract][Full Text] [Related]
19. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792 [TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing. Rosenthal SH; Sun W; Zhang K; Liu Y; Nguyen Q; Gerasimova A; Nery C; Cheng L; Castonguay C; Hiller E; Li J; Elzinga C; Wolfson D; Smolgovsky A; Chen R; Buller-Burckle A; Catanese J; Grupe A; Lacbawan F; Owen R Biomed Res Int; 2020; 2020():3289023. PubMed ID: 32090079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]